GTx Revenue and Competitors

Memphis, TN USA

Location

$163.2M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • GTx's estimated annual revenue is currently $7.5M per year.(i)
  • 0
  • GTx's total funding is $163.2M.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$5M3214%N/AN/A
#3
$3.6M235%N/AN/A
#4
$1.1M7-22%N/AN/A
#5
$1.7M110%N/AN/A
#6
$0.8M50%N/AN/A
#7
$6M3950%N/AN/A
#8
$0.9M60%N/AN/A
#9
$4.8M31-6%N/AN/A
#10
$1.9M120%N/AN/A
Add Company

What Is GTx?

GTx, Inc. is a biopharmaceutical company, founded in 1997, dedicated to the development and commercialization of therapeutic products for men’s health. The company’s drug discovery and development programs focus on small molecules that selectively target and modulate nuclear hormone receptors for estrogens and androgens.

keywords:Pharmaceuticals

$163.2M

Total Funding

N/A

Number of Employees

$7.5M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

GTx News

2022-04-19 - Magic Stick x Clarks Originals Wallabee Boots 2.0 GTX

Clarks Originals and MAGIC STICK Reunite to Rework the Wallabee Boot GTX: Equipped with a metal dock tag plate.

2022-04-17 - Early Radeon RX 6400 Review Reveals GTX 1650-Level Performance

Chinese publication Expreview shares the first review of AMD's latest Radeon RX 6400 gaming graphics card.

2022-04-06 - First discrete Intel GPU falls flat against Nvidia GTX 1650

The first discrete Intel GPU has arrived on the scene, but early tests suggest it falls flat against Nvidia's GeForce GTX 1650.

2017-09-27 - GTx Announces $48.5 Million Private Placement

MEMPHIS, Tenn.–(BUSINESS WIRE)–Sep. 26, 2017– GTx, Inc. (NASDAQ: GTXI) today announced that it has entered into a definitive securities purchase agreement for the sale of its common stock and warrants to purchase common stock in a private placement that is expected to result in gross proceeds to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$750M0N/A$54.5M
#2
$75M10%N/A
#3
$7.5M10%$4.5M
#4
$7.5M1-50%N/A
#5
$0M10%N/A